Various strategies for modifying CARs have been developed to target antigenic heterogeneity in solid tumors, one of which is the simultaneous targeting of multiple tumor antigens to provide a higher level of antigen recognition ability for infused immune cells, such as dual-targeted tandem CARs recognizing EpCAM and ICAM-1 (70), and triple-targeted CARs targeting three antigens, namely, HER2, IL-13Rα2, and EphA2, at the same time (71). Here, ICAM1 is linked to neoplasm.